Dr David Jaffray – Cone Beam CT and adaptive radiation therapy

Dr. David Jaffray from PMH is the inventor of  “Cone Beam CT”, an advanced computer tomography systems used for image-guided radiation treatment of cancer. The name of the system comes from the cone-shaped X-rays used to create a complete three-dimensional image of the patient. A number of separate cross-sectional images are used in traditional computer tomography which are put together to reproduce an image of the patient.

“Cone Beam CT” is a quicker and more sophisticated than traditional computer tomography. RaySearch’s software for adaptive radiation therapy has to ability to utilize the information on the patient’s anatomy provided by the Cone Beam CT system during treatment to calculate the change in the treatment plan for greater precision.

The purpose of adaptive radiation therapy is to take into consideration the changes in the patient’s anatomy that take place during treatment and to correct any defects or deviations. By doing so, the results of treatments are further improved.

Keith Tipton, General Manager, Philips Radiation Oncology Systems – 
Extending cooperation with Philips

Philips and RaySearch are now entering the next phase of their collaboration which is intended to develop the next generation system for inverse treatment planning. Collaboration includes methods for actively monitoring and correcting patient treatments.

“This is an important milestone for Philips’ customers in treatment planning,” says Keith Tipton, General Manager, Philips Radiation Oncology Systems. “Our collaboration with RaySearch has made it possible for us to accelerate the distribution of our leading product solutions for IMRT on the market. By incorporating both biological models and machine parameters in optimization problems, we have again been able to show that Philips has an ambition to lead developments in this important area for clinical applications. The outlook for the next phase of the cooperation with RaySearch is to be able to realize solutions that further improve the usability and the clinical work flows of Philips’ products within IMRT. This is made possible by actively handling biological and physiological changes during the patient’s entire treatment period.”

Rob Plompen, President of IBA Dosimetry– Letter of Intent with IBA Dosimetry

“The number of IMRT-based cancer treatments is increasing considerably. For a long period of time, we have been striving to provide our global customer base with first-class dosimetry solutions that enable clinics to handle the greater demands of flows of patients without needing to lower levels of accuracy or reliability of treatments. With its unique competence in radiation dosage and optimization algorithms, RaySearch Laboratories is an optimal partner for taking new leading-edge technology in IMRT quality assurance to the market,” says Rob Plompen, President of IBA Dosimetry.

Rob Plompen, President of IBA Dosimetry – Agreement with IBA Dosimetry

Rob Plompen, President of IBA Dosimetry, points out the following: “As far as continuous improvements in cancer treatments are concerned, there is not time lose. The advanced dosimetry solutions that the companies are to develop together will significantly increase the dosimetric precision before and during IMRT treatments. RaySearch’s specific expertise in dosage calculation and optimization algorithms makes the company an ideal partner for us to take this new leading-edge technology out to the market. RaySearch has acknowledged merits in the development of advanced software application in radiation therapy. We are extremely pleased about the agreement between our two companies and we look forward to our collaboration with confidence.”

Rudolf Scholte, former President of Nucletron – Letter of Intent with Nucletron

Rudolf Scholte, former President of Nucletron BV, says: “The ORBIT modules supplement OTP in an excellent manner and will make it considerably easier for hospitals and care institutions around the world to work with IMRT in cancer treatments.”

Rudolf Scholte, former President of Nucletron – Agreement with Nucletron

Rudolf Scholte, former President of Nucletron BV, says: “For the effective clinical introduction of IMRT, doctors require access to advanced multimodal image treatment and good tools for outlining organs and reliable and rapid treatment and optimization algorithms. The combination of the ORBIT modules and OTP provides an excellent integrated solution.”